Αggrafiban

Agrafiban (Tirofiban Hydrochloride Monohydrate) is an intravenous platelet aggregation inhibitor used to prevent blood clots in high-risk patients. It belongs to the glycoprotein IIb/IIIa receptor antagonists class. This medication is commonly prescribed for acute coronary syndromes. Always consult a healthcare provider for personalized guidance.

Agrafiban is used to reduce the risk of blood clots in patients with unstable angina or non-ST elevation myocardial infarction undergoing percutaneous coronary intervention. It works by preventing platelets from clumping together, which can block blood flow to the heart. This medication is typically administered in a hospital setting under medical supervision.

Agrafiban may help maintain blood flow to the heart by reducing platelet aggregation. Patients may experience improved circulation and reduced risk of clot-related complications. Common effects include mild headache or dizziness, though individual responses vary. It is not a pain reliever or anti-inflammatory agent.

Agrafiban should be used with caution in patients with a history of bleeding disorders or recent surgery. Regular monitoring of blood counts and clotting parameters is recommended during treatment. Patients should inform their doctor about all medications and medical conditions before use. Avoid activities that may increase bleeding risk while on this medication.

Agrafiban may interact with other blood thinners, antiplatelet drugs, or medications that affect clotting. Combining it with nonsteroidal anti-inflammatory drugs (NSAIDs) or certain antibiotics may increase bleeding risk. Alcohol and herbal supplements like ginkgo biloba may also pose risks. Always disclose all medications to your healthcare provider.